Myriam Chalabi: The results of the NICHE-2 study now published in NEJM
Myriam Chalabi, Medical Oncologist and Cancer Immunotherapy researcher at Antoni van Leeuwenhoek, shared a post on their LinkedIn:
”Ecstatic and proud to share the results of the NICHE-2 study now published in the New England Journal of medicine NEJM Group. This study, conducted at The Netherlands Cancer Institute, in collaboration with several hospitals in The Netherlands and with continued support from the oncology community, is a fantastic example of collaboration across disciplines and team science.
Above all, I am extremely grateful to all the patients who participated in the study, even when we did not know this treatment would be so effective. Incredibly happy that we were able to help so many.
Short summary: In the 111 patients with locally advanced dMMR colon cancer, 95% had a major pathological response, and 68% had a complete response after only two cycles of neoadjuvant immunotherapy. With a median follow-up of more than 2 years, none of these patients have had recurrence of their disease.”
Source: Myriam Chalabi/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023